[1] |
ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui.
One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305.
|
[2] |
WANG Tao, ZHENG Mingjie, LIU Hongliang, WANG Qing, SHEN Chuanyong.
Current applications of artificial intelligence in pharmacovigilance in the USA and implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1129-1133.
|
[3] |
YU Min, LI Xin.
Immunerelated adverse events and risk factors of carrelizumab in 528 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1134-1140.
|
[4] |
HUANG Ying, HOU Tiantian, QIN Chao, HUO Yan, WANG Sanlong, WEN Hairuo, GENG Xingchao.
Nonclinical research on CAR-T cell products: main concerns and key issues
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 813-816.
|
[5] |
HUANG Ying, WEN Hairuo, HOU Tiantian, HUO Yan, WANG Sanlong, GENG Xingchao.
Cloning ability of CAR-T cells in soft agar and tumorigenicity in vitro
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 836-838.
|
[6] |
CHEN Shuang, ZHENG Shufen, ZHANG Shuyao, ZHONG Shilong.
Adverse reactions of tumor immunotherapy drugs—PD-1/PD-L1 inhibitors
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1107-1112.
|
[7] |
HUANG Lihong, CHEN Feng.
Statistical considerations for real world studies supporting new drug registrations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 27-31.
|
[8] |
Chen Aihong, Yin Qiangbing, Li Huadan, Wu Nengjian.
Analysis of Monitoring Reports on Suspected Adverse Events Following Immunization in Pingshan District Shenzhen City during 2015~2018
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 464-468.
|
[9] |
YANG Ming, LUO Hui, LIU Jianping.
Progress in Methods of Research into Clinical Interactions between Traditional Chinese Medicine and Chemical Medicine
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1029-1033.
|
[10] |
CHENG Jinlian, OUYANG Huitian, JIN Hongtao, ZHU Xueqi, XIAO Shuang, LEI Xiang, GAO Chunsheng, LIU Qingquan.
Thoughts and Suggestions on Safety Evaluation of Combined use of Traditional Chinese Medicine in Clinical Research
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(1): 4-10.
|
[11] |
LI Xinxu, TANG Zhimin, ZHOU Jun, WANG Jun.
Limitations of the Safety Assessment in Premarketing Clinical Trials of Drugs and Suggestions for Improvement
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 465-470.
|
[12] |
JIANG RuiJu, YIN QiongZhou, XU MingJue, ZHAO ZhiMei, DENG Yan, NING Ruotong, CHE YanChun.
Adverse Events Induced by Immunization of Concomitant Inoculation of Freeze-dried Hepatitis A (Live) Vaccine with Vaccines for National Immunization Program from Surveillance Data
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 710-714.
|
[13] |
SUN Yixin, MENG Kangkang, XIA Yukun, XIONG Weiyi, DENG Siwei, DONG Duo, ZHAN Siyan.
Incidence of Cardiac Adverse Events of Cisapride: a Systematic Review and Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(2): 94-100.
|
[14] |
LIANG Xinyuan, MO Yi, FENG Shuo, YANG Huan, MO Zhaojun.
Development and Safety Monitoring of Electronic Data Capture System for Vaccine Clinical Trials
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 711-715.
|
[15] |
WAN Bangxi, YU Lina, XU Juping.
Data Quality of Individual Case Safety Reports Based on ICH E2B (R3) Implementation Guidelines
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(10): 597-601.
|